35 results about "Basal bolus" patented technology

The present disclosure relates to poly alpha-1,6-glucan ether compounds comprising poly alpha-1,6-glucan substituted with at least one positively charged organic group and having a degree of substitution of about 0.001 to about 3.0. The poly alpha-1,6-glucan comprises a backbone of glucose monomer units, wherein greater than or equal to 40% of the glucose monomer units are linked via alpha-1,6 glycosidic bonds, and optionally about 3% of the backbone glucose monomer units have branches via alpha-1,2 and / or alpha-1,3 glycosidic bonds. Compositions comprising poly alpha-1,6-glucan ether compounds can be used in various applications.

The invention relates to a lipid molecule, and a composition and application thereof. The core structure of the lipid-like molecule covers a two-dimensional plane structure and a plurality of three-dimensional structures, and endows the LNP with adjustable membrane tissue characteristics and intracellular transport behaviors, so that a new strategy of adjusting delivery performance from the structural level is realized. In addition, part of the ionizable lipid is introduced into a fluorine substituent group, so that the internal hydrophobic interaction and colloidal stability of the LNP are improved, and the in-vivo delivery persistence is prolonged. The invention also provides a component-simplified LNP delivery system based on programmable regulation and control of ionizable lipid chemical bonds, which is different from the traditional strategy of needing to remove hepatic tropism components (such as cholesterol) or additionally introduce targeted regulation and control lipid (a fifth component) to realize organ targeting. Selective delivery of organs such as liver, spleen, lung, pancreas and the like can be realized under the condition of retaining cholesterol only by changing the type of a chemical bond between an aliphatic chain and a core structure in the ionizable lipid.

The present invention belongs to the technical field of insulin derivatives. Disclosed are a phenylboronic-acid-based insulin derivative, and a preparation method therefor and the use thereof. The provided phenylboronic-acid-based insulin derivative has a good glucose-responsive release function, wherein the phenylboronic acid group binds to a glycosyl protein to generate a phenylboronic acid ester bond, thereby generating an insulin and glycosyl protein complex in situ in blood. When the concentration of glucose in the blood is high, the glucose specifically cleaves the phenylboronic acid ester bond, thereby releasing the insulin. The provided phenylboronic-acid-based insulin derivative achieves stable and rapid glucose-responsive insulin release, which can steadily and persistently maintain the blood glucose of a diabetic subject within the normal range with almost no occurrence of hypoglycemia.

The invention relates to the technical field of food-grade materials, in particular to a food-grade porous material and a preparation method thereof. The preparation method comprises the following steps: gradually carrying out enzymolysis on corn flour by alkaline protease and amylase under the conditions of proper temperature and pH, continuously stirring, adding food-grade vegetable gum, and forming porous glycoprotein under the assistance of ultrasonic waves; the porous glycoprotein is uniform in pore size and is 0.5-3 microns, and the surface of the porous glycoprotein is rich in functional groups, so that the porous glycoprotein has good adsorption performance and has very high adsorbability on hydrophobic compounds such as metal ions, pesticide residues, kitchen oil stains and the like. The preparation process is simple, chemical reagents do not need to be introduced, and safe and non-toxic substances are completely adopted as materials for preparing the porous material, so that the product is food-grade, small in damage to human bodies and the environment and wide in application in the food field.

The invention discloses a partial acylated non-natural sugar for metabolic labeling and application, the partial acylated non-natural sugar is a mannose type of a pyranose structure, and 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups. According to the method, the advantages of existing non-natural sugar are taken into consideration, it is guaranteed that the non-natural sugar can be efficiently utilized by cells, S side reaction of the non-natural sugar and cysteine in protein in the metabolism process is effectively avoided, and meanwhile efficient metabolism marking is achieved. In a cell test, the use concentration of the 1, 6-diacylated non-natural sugar is one order of magnitude lower than that of the non-natural sugar without the protecting group.

The invention belongs to the technical field of protein beverages, and particularly relates to a composite peptide beverage and a preparation process thereof. The active ingredients of the drink comprise calf thymosin, cattle spleen protein peptide, hemoglobin peptide, bone collagen peptide and collagen peptide in a weight ratio of (2-3): 1: 1: 1: 1. The pH value of the system is adjusted to 3.5-4.5, so that each peptide molecule is positively charged under the acidic condition, the electrostatic repulsion and hydration among molecules are enhanced, and bitter groups are effectively masked. The flavoring agent is compounded by DL-malic acid, crystalline fructose, xylitol and sucralose according to the weight ratio of (0.6-1): 1: 0.4: (0.03-0.04), and the sour and sweet taste and flavor coordination are synergistically improved. The preparation method comprises the following steps: dissolving the DL-malic acid in purified water, dissolving the uniformly mixed active components in purified water at 40-60 DEG C, respectively adding other flavoring agents, stabilizing agents and essence, and finally filtering to obtain the product. The problem of bad flavor of the peptide is solved, so that the beverage is appropriate in taste, harmonious in flavor and easy to accept.

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 1 is CH or N, p is 0, 1, or 2, where each R 1 is a substituent on any C atom and is independently selected from F, Cl, C 1~3 alkyl, and C 1~3 alkoxy, and the C 1~3 alkyl and C 1~3 alkoxy may each be optionally substituted by one or more Fs, R N is selected from H and Me, n is 0, 1, or 2, m is 0 or 1, Q 1 is CH or N, and when both n and m are other than 0, Q 2 is CH or N, and when both n and m are 0, Q 2 is CH, and when n is 0 or 1, Q 3 is CH, and when n is 2 and Q 2 is N, Q 3 is CH, and when n is 2 and Q 2 is CH, Q 3 is CH or O, and R 2a and R 2b are substituents on the same or different C atoms other than Q 1 or Q 2 and are each independently selected from H, F, and C 1~3 alkyl, or R 2a and R 2b together form a -(CH2) r - group, where r is 1, 2, or 3, Q 4 is a single bond or -NR 4 C(=O), R 4 is H or Me, Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 of which 0, 1, or 2 are N and otherwise C, and each R 3 is Y1, Y 2 , Y 3 , Y 4 , and Y 5A substituent on any C atom, independently of F, Cl, CN, C 1~3 Alkyl and C 1~3 Selected from alkoxy, the C 1~3 Alkyl and C 1~3 The alkoxy can be independently and optionally substituted by one or more Fs, where q is 0, 1, or 2, and the linker is Y. 4 and Y 5 A compound of formula (I) or a pharmaceutically acceptable salt thereof, bonded at any available C atom, the linker being a saturated, partially or fully unsaturated skeleton comprising C and H atoms and at least one heteroatom, the skeleton having bond endpoints "a" and "b" and having a length of 5 to 26 atoms between "a" and "b", the skeleton may contain one or more linear and / or branched and / or ring chains, optionally substituted on any available C atom with one or more F, and W being an E3 ubiquitin ligase cereblon binding unit. [Formula 1] JPEG2026510359000635.jpg38128

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

A drug delivery system for administering a GLP-1 agonist therapy includes a reservoir configured to contain a GLP-1 agonist, a pump in fluid communication with the reservoir and configured to deliver the GLP-1 agonist, a controller operatively coupled to the pump, and a user interface operatively coupled to the controller. The controller is programmed to deliver a basal dose of the GLP-1 agonist continuously over a 24-hour period and deliver at least one bolus dose of the GLP-1 agonist in addition to the basal dose. The system allows for independent adjustment of basal and bolus doses based on patient-specific parameters, enabling personalized GLP-1 agonist therapy administration.

The invention relates to the technical field of biological medicine, in particular to a compound and a preparation method thereof, a photo-thermal agent and application of the photo-thermal agent in obesity treatment. The compound has a structure as shown in a formula I in the specification, wherein R is selected from at least one of anthracene-containing groups, dibenzothiophene-containing groups or carbazole-containing groups, and X is selected from at least one of halogen atoms, PF6 <-> and BF4 <->. The compound provided by the invention has mitochondrial targeting property and good photothermal conversion capability, and can realize obesity treatment by promoting the browning process of white adipose tissues.

The application discloses a sulfonated MXene sensing layer, a preparation method thereof and a biosensor, and belongs to the technical field of electrochemical sensors. The sensing layer contains a sulfonated MXene material, and the sulfonated MXene material is obtained by covalently grafting sulfonic acid groups on the MXene material. The sulfonic acid groups are covalently grafted on the surface of the MXene through plasma treatment, so that the sulfonic acid groups have high specific surface area, excellent electron conductivity, high enzyme immobilization capacity and H2O2 catalytic decomposition activity. The biosensor based on the sensing layer comprises a flexible substrate, a three-electrode system and a diffusion-limiting layer, and the response speed, detection accuracy, stability and anti-interference performance (such as anti-uric acid and anti-ascorbic acid) of the biosensor are significantly improved, and the biosensor is particularly suitable for applications in an implantable continuous glucose monitoring system.

The invention relates to a fat composition and a nutritional composition comprising such fat composition. The nutritional composition is particularly suitable for therapeutic applications in treating gut discomfort and / or constipation as well as in non-therapeutic applications for reducing the intestinal formation of calcium and magnesium fatty acid soaps. The fat composition comprises a mixture of triacylglycerols (TAG) originating from a bovine milk fat source and a vegetable lipid source, said mixture being characterized by: (a) a content of butanoate groups (C4:0) of 0.5-2.8% by weight based on total weight of fatty acid acyl groups in TAG; (b) a wLCSFA(sn-1,3) of 18.0-35.0% by weight; (c) a mLCFA (sn-1,3) of 48.0-61.0 mol %; and (d) a ratio mLCFA (sn-1,3) / SFA of 0.70-1.25, wherein: —LCFA(sn-1,3) are the long chain fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —LCSFA(sn-1,3) are the long chain saturated fatty acid acyl groups having a chain length of 12 or more carbon atoms at the sn-1 and sn-3 position in TAG; —wLCSFA(sn-1,3) is the amount of LCFA(sn-1,3) in % by weight based on total weight of fatty acid acyl groups in TAG; —mLCFA(sn-1,3) is the mole fraction of LCFA(sn-1,3) based on total moles of fatty acid acyl groups in the TAG as expressed in mol %; and—SFA is the mole fraction of saturated fatty acid acyl groups in the TAG as expressed in mol %.

This invention discloses a method for determining glucose content in embryo culture medium. In this invention, proteins and amino acids are filtered from the sample using ultrafiltration centrifuge tubes. High-performance liquid chromatography (HPLC) is used as the detector, and an external standard curve method is employed to detect the glucose content in the embryo culture medium. The pretreatment step of ultrafiltration centrifuge tube filtration eliminates interference from human serum albumin and some amino acids in the embryo culture medium on the determination of the target component, glucose. An amino-based column is specifically selected; the hydroxyl groups in glucose form hydrogen bonds with the amino groups on the stationary phase of the amino-based column, separating them from other components in the culture medium under the action of the mobile phase, thus achieving separation. The method uses a differential detector to establish an external standard curve for quantitative determination, which is characterized by rapid and simple operation, good repeatability, and accurate results, making it suitable for determining glucose content in embryo culture medium.

Described herein is a beta-glycoside of structural formula (I) wherein X1 or X2 is-C (= O) OR, R is an alkyl group comprising from 1 to 6 (1 to 4) carbon atoms, and Y is a monovalent sugar selected from the group consisting of beta-D-glucose, beta-D-galactose, beta-D-glucuronic acid, N-acetylglucosamine or galactosamine, where when X1 is-C (= O) OR then X2 is-H, and when X2 is-C (= O) OR then X1 is-H. Such beta-glycosides can be used as indicators, such as biological indicators. (I)

The present invention provides PYY analogs that are neuropeptide Y2 (NPY2) receptor agonists, their medical use in the treatment and / or prevention of various diseases, conditions, or disorders, such as the treatment and / or prevention of excessive food intake, excess weight, adiposity, metabolic diseases, and other conditions or disorders associated with excess weight or adiposity, such as diabetics and cardiovascular diseases.SOLUTION: The present invention relates to PYY analogues having alanine in position 4, lysine in position 7, QRY as C-terminus and a half-life extending group. The analogs of the present invention are soluble in pH6 and around 7. The invention also relates to pharmaceutical compositions comprising the PYY analogues and to pharmaceutical uses of the analogues.SELECTED DRAWING: None

A drug delivery system for administering a GLP-1 agonist therapy includes a reservoir configured to contain a GLP-1 agonist, a pump in fluid communication with the reservoir and configured to deliver the GLP-1 agonist, a controller operatively coupled to the pump, and a user interface operatively coupled to the controller. The controller is programmed to deliver a basal dose of the GLP-1 agonist continuously over a 24-hour period and deliver at least one bolus dose of the GLP-1 agonist in addition to the basal dose. The system allows for independent adjustment of basal and bolus doses based on patient-specific parameters, enabling personalized GLP-1 agonist therapy administration.

The invention relates to a preparation method and application of sugar-responsive protamine insulin, which comprises the following steps: modifying a chemical group on cysteine of protamine, connecting with a phenylboronic acid compound to form a compound, and mixing with insulin to prepare the sugar-responsive protamine insulin. The sugar-responsive insulin preparation can realize an intelligent sugar-responsive regulation mechanism. Specifically, the insulin can be slowly released at a normal blood glucose level and is accelerated to be released at a hyperglycemia state, so that the blood glucose is effectively regulated and controlled, and the occurrence of hypoglycemia is avoided.

This invention relates to a method for preparing glucose-responsive protamine insulin and its application. The method involves modifying chemical groups on the cysteine ​​residues of protamine and linking them with phenylboronic acid compounds to form a complex, which is then mixed with insulin to prepare glucose-responsive protamine insulin. This glucose-responsive insulin formulation achieves an intelligent glucose response regulation mechanism. Specifically, under normal blood glucose levels, the insulin is released slowly, while under hyperglycemic conditions, its release is accelerated, thereby achieving effective blood glucose control and preventing hypoglycemia.

The present disclosure relates to novel compounds comprising one or more aromatic boron-containing groups, including diborates, and methods of making the disclosed compounds. The present disclosure also relates to pharmaceutical compositions comprising the disclosed compounds, and their use in the prevention and treatment of diseases and disorders, such diseases and disorders include hyperglycemia, type 2 diabetes mellitus, impaired glucose tolerance, type 1 diabetes mellitus, obesity, metabolic syndrome X or dyslipidemia, gestational diabetes mellitus, prediabetes mellitus, Alzheimer's disease, MODY 1, MODY 2 or MODY 3 diabetes mellitus, mood disorders, and mental disorders.

A compound of formula (I), a stereoisomer, a pharmaceutically acceptable salt, a solvate and / or hydrate thereof: where R1 is H, XYZ or where L is a leftist; X is selected from the group consisting of C=O, C=S, C=NH, C=N-Me, C=N-OH, C=NO-Me, S=O, SO2 and CH2; Y is selected from the group consisting of O, S, NH, Aryl, Heteroaryl, Selenophenyl, linear or branched C 1-12 -Alkyl, optionally substituted with one or more R 10 , linear or branched C 1-12 -Alkyl ether, optionally substituted with one or more R 10 , linear or branched C 1-12 -Alkylamine, optionally substituted with one or several R 10 , linear or branched C 1-12 -Thioalkyl, optionally substituted with one or more R 10 , linear or branched C 1-12-Alkyl selenoethers, optionally substituted with one or more R 10 , linear or branched C 1-12 -Alkylcarbonyl, optionally substituted with one or more R 10 , OP(=O)(ORa)2, OP(=O)(ORa)(ORb), OP(=O)(ORa)(Ra), OP(=O)(ORa)(Rb), OP(=O)(Ra)2, OP(=O)(Ra)(Rb), P(=O)(ORa)2, P(=O)(ORa)(ORb), P(=O)(ORa)(Ra), P(=O)(ORa)(Rb), P(=O)(Ra)2 and P(=O)(Ra)(Rb), where Ra and Rb each independently of each other C 3-10 -Cycloalkyl and / or linear or branched C 1-12 -Alkyl groups, optionally substituted with one or more R groups 10 , where R 10 selected from the group consisting of halogens, OH, NH2, SH, linear or branched C 1-6 -Perfluoroalkyl, linear or branched C 1-12 -Alkylthiol, linear or branched C 1-12 -Alkyl selenoethers, linear or branched C 1-12 -Alkylselenol, linear or branched C 1-12-Alkylether, linearem oder verzweigtem C 1-6 Alkylcarbonyl und linearem oder verzweigtem C 1-12 -Thioalkyl; Z abwesend oder ausgewählt ist aus der Gruppe bestehend aus H, O-P(=O)(OR a )2, O-P(=O)(OR a )(OR b ), O-P(=O)(OR a )(OR c ), O-P(=O)(OR c )2, O-P(=O)(OR a )(R a ), O-P(=O)(OR a )(R b ), O-P(=O)(OR a )(R c ), O-P(=O)(OR c )(R c ), O-P(=O)(R a )2, O-P(=O)(R c )2, O-P(=O)(R a )(R b ), O-P(=O)(R a )(R c ), P(=O)(OR a )2, P(=O)(OR a )(OR b ), P(=O)(OR c )2, P(=O)(OR a )(OR c ), P(=O)(OR a )(R a ), P(=O)(OR a )(R b ), P(=O)(OR a )(R c ), P(=O)(OR c )(R c ), P(=O)(R a )2, P(=O)(R a )(R b), P(=O)(R c )2, P(=O)(R a )(R c ), Si(R a )2(Ph), Si(R a )(R b )(Ph), Si(R a )2(CH2Ph), Si(R a )(R b )(CH2Ph), Si(R a )2(R d ), Si(R a )(R b )(R d ), Si(R a )2 (CH2R c ), Si(R a )(R b )(CH2R c ), Si(R c )3, Si(CH2R c )3, linear or branched C 1-12 -Alkyl selenoether, B(OR e )2, B(OCH(CH2)2)2, where R a and R b each linear or branched C 1-12 -Alkyl are; R c is C 3-10 -Cycloalkyl; R d is C 3-10 -Cycloalkenyl; R e is linear or branched C 1-6 -Alkyl and / or wherein C 1-12 -Alkyl selenoether is linear or branched; R2 and R6 are each independently selected from the group consisting of H, B(OH)2, B(OR 11)2 and B(OR 11 )(OR 12 ); where R 11 and R 12 Each is selected independently from the group consisting of linear or branched C 1-12 -Alkyl and linear or branched C 1-12 -Alkylcarbonyl; R3 and R7 are each independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkylmethyl, cycloalkyl, cycloalkylalkyl, carbocycle, heterocycle, methylazetidinyl and (1-methylazetidin-3-yl)methyl, where alkyl is linear or branched C 1-4 -Alkyl is optionally substituted with one or more OH and / or halogen atoms; alkenyl is linear or branched C 2-4 -Alkenyl, optionally substituted with one or more halogen atoms; alkynyl is linear or branched C 2-4 -Alkynyl, optionally substituted with one or more halogen atoms, cycloalkyl is C 3-6-Cycloalkyl, optionally substituted with one or more halogen atoms; R4, R5, R8 and R9 are each independently selected from the group consisting of H, C 3-5 -Cycloalkyl, C 1-5 -Alkyl, where the C 1-5 -Alkyl is linear or branched, optionally substituted with one or more halogen atoms or trifluoromethyl groups; or R4 and R5 together form part of a C 3-6 -Carbocycle or one C 3-6 -Heterocycle; or R8 and R9 together form part of a C 3-6 -Carbocycle or one C 3-6 -Heterocycle; provided that if R1 and R2 are both H, R4 and R5 are not both ethyl groups, and R3 is not a methyl group.

The present invention relates to a compound of formula (I): [Chemical Formula 1] (I) In the above formula, n1 and n2 are each integers from 0 to 15, R1, R2, R3, R4, R5 and R6 are each independently selected from H, OH, SH, NH2, SO3R10 and X-R11-Y, R10 and R'10 are independently H, Na or K, X, X' and X'' are independently O, S or NH, R11, R'11 and R''11 are selected from C1 to C15 alkyl, aryl, heteroaryl, (C1 to C15 alkyl)aryl, (C1 to C15 alkyl)heteroaryl, aryl (C1 to C15 alkyl), and heteroaryl (C1 to C15 alkyl); Y, Y' and Y'' are independently selected from H, halogen, COOR'10, or amide; R7 and R8 are each independently selected from H, OH, SH, NH2, C1 to C15 alkyl and X'-R'11-Y'; R9 is selected from H, OH, SH, NH2 and X''-R''11-Y'', and The above compound is a compound comprising at least one group X-R11-Y, X'-R'11-Y', or X''-R''11-Y'' where Y, Y' and / or Y'' is COOR'10. The present invention also relates to a method for preparing a compound of Formula I according to the present invention, as well as a method for labeling tumor tissue with one of the compounds prepared according to the present invention or according to the method of the present invention.

The present invention relates to a polymeric nanoparticle for oral administration of physiologically active substances and a preparation method therefor and, more specifically, to a carrier or polymeric hydrogel for delivery of a physiologically active substance and a preparation method therefor, wherein the carrier or polymeric hydrogel comprises: polymeric micelles including a PEG-based block copolymer prepared by a reversible addition–fragmentation chain transfer (RAFT) radical polymerization method using a polymer that has a specific functional group at the chain end thereof and a boronic acid group introduced into the backbone thereof; and a physiologically active substance that can be encapsulated in the polymeric micelles, including a type 2 diabetes drug, insulin, an anti-obesity agent, a DPP-4 inhibitor, or an anticancer agent.

A compound A-L-B, wherein A is a nanoparticle (NP)-forming unit, preferably a NP-forming polypeptide or a NP-forming protein, preferably a NP-forming polypeptide or a NP-forming protein having its C-terminus covalently bound to the N-terminus of L via a peptide bond; L is a polypeptide having the following amino acid sequence written in the single letter code z1–G X1 X2 G X3 G X4 X5 G X6 G X7 G–z2, wherein X1 = any amino acid except H, C, and W, X2 = any amino acid except H, C, and W, X3 = any amino acid except H, C, and W, X4 = any amino acid except H, C, and W, X5 = any amino acid except H, C, and W, X6 = any amino acid except H, C, and W, X7 = any amino acid except H, C, and W, z1 represents the N-terminus of the polypeptide, or a group consisting of 1 to 10 amino acids, and z2 represents the C-terminus of the polypeptide, or a modification of the C- terminal carboxyl group of the polypeptide, which modification (i) forms together with the carboxyl group of the C-terminal amino acid of the polypeptide a moiety having the structure -C(O)-O-R1 or -C(O)-NR2R3, wherein R1 is a functional group selected from the group consisting of -(CH2)n-N3, -(CH2)n-C≡CH, -(CH2)n-difluorooctyne (DIFO), and -(CH2)n-dibenzylcyclooctyne (DIBO); and wherein one of R2 and R3 is H and the other one is a functional group selected from the group consisting of -(CH2)n-N3, -(CH2)n-C≡CH, -(CH2)n-difluorooctyne (DIFO), and -(CH2)n-dibenzylcyclooctyne (DIBO); wherein n = 1, 2, 3, 4, or 5; or (ii) is a polypeptidic catcher group which is able to form an isopeptide bond with a polypeptidic tag group in a catcher / tag pair reaction; or (iii) is a Staphylococcus aureus sortase A transpeptidase recognition site consisting of the amino acids LPXTG, being attached to the C-terminus of the polypeptide via a peptide bond; wherein the side chain of each amino acid of the polypeptide L independently of each other may be chemically modified, in particular phosphorylated, amidated, acetylated, glycosylated, PEGylated, HESylated or combinations thereof; and B is a compound having biological activity, preferably a protein, which preferably has its N-terminus covalently bound to the C-terminus of L via a peptide bond; wherein the N-terminus of L is covalently bound to A, preferably via a peptide bond, and wherein the C-terminus of L is covalently bound to B, preferably via a peptide bond.

The invention relates to the technical field of biological small molecule fluorescence detection, and discloses an amino-bridged tetraphenylethylene phenylboronic acid ester compound, a synthesis method and application thereof and a glucose fluorescence detection method. Tetraphenylethylene is used as an aggregation-induced emission mother nucleus of the compound, a quaternized amino-bridged biphenylboronic acid recognition group is used, and the compound can be used for detecting glucose. The probe can be specifically combined with glucose to generate an aggregation-induced emission effect; the invention also provides a two-step synthesis method of the compound, the synthesis route is simple, the conditions are mild, and the product purity and yield are stable; the glucose detection method constructed based on the compound avoids inherent defects of traditional enzyme method detection, improves water solubility of sensing molecules and glucose binding dynamics performance, has the advantages of being high in detection sensitivity, wide in linear range, easy and convenient to operate and high in anti-interference capacity, and is suitable for rapid quantitative detection of glucose in a water phase system.

A laundry care or dish care composition can include a poly alpha-1,6-glucan derivative, wherein the poly alpha-1,6-glucan derivative includes: (i) a poly alpha-1,6-glucan backbone of glucose monomer units; and (ii) at least one hydrophobic organic group linked to the poly alpha-1,6-glucan backbone through an ether (—O—) linkage moiety; wherein, the poly alpha-1,6-glucan backbone has a weight average degree of polymerization of at least 5; wherein, the poly alpha-1,6-glucan derivative has a degree of substitution of ether linkage moiety of from 0.20 to 1.00; wherein the poly alpha-1,6-glucan derivative is substantially free from hydrophilic substitution.

This invention provides a glucose-sensitive and antifouling bifunctional probe, its preparation method, and its application, belonging to the field of glucose detection technology. It addresses the problems of poor sensitivity and antifouling stability in existing biological probes used for glucose detection. The preparation method of the glucose-sensitive and antifouling bifunctional probe includes: preparing a phenylboronic acid hydrogel membrane as a glucose-sensitive functionalized probe; mixing 2-bromoisobutyric acid, 3,4-bis(tert-butyl-dimethyl-siloxy)-1-phenylalanine, and a chemical bridge containing a primary amine group, and performing an amidation reaction to obtain an ATRP initiator; mixing an antifouling monomer and the ATRP initiator, and performing an ATRP reaction to obtain an antifouling coating solution; wherein the chemical bridge containing the primary amine group is 1,3-diamino-isopropanol and / or pentaerythritol; and spin-coating the antifouling coating solution onto the surface of the phenylboronic acid hydrogel membrane of the glucose-sensitive functionalized probe to obtain a glucose-sensitive and antifouling bifunctional probe with an antifouling coating. This glucose-sensitive and antifouling bifunctional probe exhibits high sensitivity and antifouling stability.

The present invention relates to a heterocyclic compound, and a preparation method therefor and a pharmaceutical use thereof. Specifically, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition or health care product containing same, a use thereof in the prevention or treatment of muscle atrophy and wasting-related diseases, including myogenic muscle atrophy, disuse muscle atrophy, sarcopenia, and neurogenic muscle atrophy, and a use thereof in the prevention and / or treatment of obesity, fatty liver, cardiovascular and cerebrovascular diseases, metabolic diseases, and anti-aging. The definition of each group in the general formula (I) is the same as that in the description.

The invention relates to a method for the production of complexes of iron (III) hydroxide with activated glucose syrup and pharmaceutical compositions containing the complexes, wherein the molecular weight of the complex ranges from 115 to 140 kDa, preferably 120 to 130 kDa, as measured by high-performance liquid chromatography (HPLC - GPC) which comprises the following steps: 1) providing an aqueous solution of glucose syrup, having a dextrose equivalent (DE) of at least 30 to at most 50, preferably between 30 and 40, 2) hydrogen peroxide and optionally an oxidation catalyst are added to the solution of step (1), then the solution is cooled, so as to obtain the activated glucose syrup, 3) the aforementioned activated glucose syrup is converted into a complex with iron (III) hydroxide, 4) a complex of iron (III) hydroxide and activated glucose syrup is obtained, having more than two -COOH groups per glucose molecule.

A laundry care or dish care composition can include a poly alpha-1,6-glucan derivative, wherein the poly alpha-1,6-glucan derivative includes:(i) a poly alpha-1,6-glucan backbone of glucose monomer units, wherein greater than or equal to 80% of the glucose monomer units are linked via alpha-1,6 glycosidic linkages, and wherein from about 10% or less of the glucose monomer units are linked via alpha-1,3 glycosidic linkages, 1,2 glycosidic linkages, and / or 1,4 glycosidic linkages; and(ii) at least one organic group linked to the poly alpha-1,6-glucan backbone through a linkage moiety;wherein, the poly alpha-1,6-glucan backbone has a weight average degree of polymerization of at least about 5;wherein, the poly alpha-1,6-glucan derivative has a degree of substitution of linkage moiety of from about 0.20 to about 1.00.